Pharmacokinetics of flunixin meglumine in the cow

Hardee, Gregory E.; Smith, J A; Harris, Stephanie

doi:10.1016/s0034-5288(18)31783-1

Cited by 54 publications

(50 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Distribution half‐life was 0.55 hr; elimination half‐life was 3.7 hr; volume of distribution at steady‐state was 0.18 L/kg; volume of the central compartment was 0.079 L/kg; and total body clearance was 1.07 ml min −1 kg −1 . The pharmacokinetic parameters determined for the herein Ilium Flunixil ® IV Injection greyhound study, as shown in Table , are entirely consistent with the results from the Hardie et al () publication. Plasma concentrations fell to as low as 0.5 ng/ml at 48 hr, below the range of 10–50 ng/ml levels of detection in these previous studies.…”

Section: Discussionsupporting

confidence: 84%

“…The plasma concentrations of flunixin and the fit to a two‐compartment model gave similar pharmacokinetic parameters to what has previously been observed (Hardie et al, ; McKellar et al, ; Ogino et al, ). Hardie et al () carried out an IV pharmacokinetic study of flunixin meglumine in six intact, awake dogs. Plasma samples were collected up to 12 hr after IV administration of flunixin meglumine.…”

Section: Discussionsupporting

confidence: 80%

“…There have been a number of previous studies of the pharmacokinetics of flunixin in dogs. Plasma pharmacokinetics have been reported by Hardie, Hardee, and Rawlings () for up to 12 hr after IV administration and by McKellar et al () and Ogino, Mizuno, Ogata, and Takahashi () for 24 hr after oral and subcutaneous administration, respectively. The range of levels of detection was 10–50 ng/ml in these studies.…”

Section: Introductionmentioning

confidence: 83%

See 2 more Smart Citations

Plasma and urine pharmacokinetics of intravenously administered flunixin in greyhound dogs

Morris

Paine

Zahra

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Medication control in greyhound racing requires information from administration studies that measure drug levels in the urine as well as plasma, with time points that extend into the terminal phase of excretion. To characterize the plasma and the urinary pharmacokinetics of flunixin and enable regulatory advice for greyhound racing in respect of both medication and residue control limits, flunixin meglumine was administered intravenously on one occasion to six different greyhounds at the label dose of 1 mg/kg and the levels of flunixin were measured in plasma for up to 96 hr and in urine for up to 120 hr. Using the standard methodology for medication control, the irrelevant plasma concentration was determined as 1 ng/ml and the irrelevant urine concentration was determined as 30 ng/ml. This information can be used by regulators to determine a screening limit, detection time and a residue limit. The greyhounds with the highest average urine pH had far greater flunixin exposure compared with the greyhounds that had the lowest. This is entirely consistent with the extent of ionization predicted by the Henderson–Hasselbalch equation. This variability in the urine pharmacokinetics reduces with time, and at 72 hr postadministration, in the terminal phase, the variability in urine and plasma flunixin concentrations are similar and should not affect medication control.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 83%

See 1 more Smart Citation

Plasma and urine pharmacokinetics of intravenously administered flunixin in greyhound dogs

Morris

Paine

Zahra

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…The plasma drug disposition of FM was investigated in cattle following i.v. administration and different t ½β values have been reported by Landoni et al ., (1995), 6.87 h (2.0 mg/kg); Hardee et al ., (1985), 8.1 h (1.1 mg/kg) and Anderson et al . (1990), 3.14 h (1.1 mg/kg).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep

Cheng

McKeller

Nolan

1998

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Flunixin meglumine (FM, 1.1 mg/kg) and phenylbutazone (PBZ, 4.4 mg/kg) were administered intravenously (i.v.) as a single dose to eight sheep prepared with subcutaneous (s.c.) tissue-cages in which an acute inflammatory reaction was stimulated with carrageenan. Pharmacokinetics of FM, PBZ and its active metabolite oxyphenbutazone (OPBZ) in plasma, exudate and transudate were investigated. Plasma kinetics showed that FM had an elimination half-life (t1/2beta) of 2.48 +/- 0.12 h and an area under the concentration - time curve (AUC) of 30.61 +/- 3.41 Lg/mL x h. Elimination of PBZ from plasma was slow (t1/2beta = 17.92 +/- 1.74 h, AUC = 968.04 +/- microg/mL x h). Both FM and PBZ distributed well into exudate and transudate although penetration was slow, indicated by maximal drug concentration (Cmax) for FM of 1.82 +/- 0.22 microg/mL at 5.50 +/- 0.73 h (exudate) and 1.58 +/- 0.30 microg/mL at 8.00 h (transudate), and Cmax for PBZ of 22.32 +/- 1.29 microg/mL at 9.50 +/- 0.73 h (exudate) and 22.07 +/- 1.57 microg/mL at 11.50 +/- 1.92 h (transudate), and a high mean tissue-cage fluids:plasma AUClast ratio obtained in the FM and PBZ groups (80-98%). These values are higher than previous reports in horses and calves using the same or higher dose rates. Elimination of FM and PBZ from exudate and transudate was slower than from plasma. Consequently the drug concentrations in plasma were initially higher and subsequently lower than in exudate and transudate.

show abstract

“…3,9 Attractive candidates for long-acting pain relief are non-steroidal anti-inflammatory drugs (NSAIDs). The pharmacokinetics of NSAIDs such as carprofen, ketoprofen and flunixin have been well documented in cattle, [10][11][12] horses 13,14 and sheep. [15][16][17] There are reports describing the efficacy of NSAIDs to alleviate pain in sheep when administered via subcutaneous, intramuscular and intravenous routes.…”

mentioning

confidence: 99%

Randomised trial of the bioavailability and efficacy of orally administered flunixin, carprofen and ketoprofen in a pain model in sheep

Marini

Pippia²,

Colditz

et al. 2015

Aust Veterinary J

View full text Add to dashboard Cite

show abstract

Pharmacokinetics of flunixin meglumine in the cow

Cited by 54 publications

References 5 publications

Plasma and urine pharmacokinetics of intravenously administered flunixin in greyhound dogs

Plasma and urine pharmacokinetics of intravenously administered flunixin in greyhound dogs

Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep

Randomised trial of the bioavailability and efficacy of orally administered flunixin, carprofen and ketoprofen in a pain model in sheep

Contact Info

Product

Resources

About